Chemotherapy induced DNA damage response Convergence of drugs and pathways

Cancer Biology and Therapy

Volumn 14, Issue 5, 2013, Pages 379-389

  Woods, Derek ^a   Turchi, John J ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

ATM; ATR; Chemotherapy; Cisplatin; DNA damage; DNA PK; PIKK; Signaling

Indexed keywords

ANTIBIOTIC C 1027; ATM PROTEIN; ATR PROTEIN; BENDAMUSTINE; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYTARABINE; DNA DEPENDENT PROTEIN KINASE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; MELPHALAN; OXALIPLATIN;

BREAST CANCER; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CELL DEATH; CELL SURVIVAL; COLON CANCER; DNA DAMAGE; DNA RESPONSIVE ELEMENT; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MULTIPLE MYELOMA; NEOPLASM; OVARY CANCER; REVIEW; SIGNAL TRANSDUCTION; TESTIS CANCER;

ATM; ATR; CHEMOTHERAPY; CISPLATIN; DNA DAMAGE; DNA-PK; PIKK; SIGNALING;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DEATH; CELL SURVIVAL; CISPLATIN; DNA DAMAGE; HUMANS; SIGNAL TRANSDUCTION;

EID: 84877842420     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.23761     Document Type: Review

References (81)

1. Meek K, Dang V, Lees-Miller SP. DNA-PK: the means to justify the ends? Adv Immunol 2008; 99:33-58; PMID:19117531; http://dx.doi.org/10.1016/S0065- 2776(08)00602-0.
2. Falck J, Coates J, Jackson SP. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 2005; 434:605-11; PMID:15758953; http://dx.doi.org/10.1038/nature03442.
3. Shiotani B, Zou L. Single-stranded DNA orchestrates an ATM-to-ATR switch at DNA breaks. Mol Cell 2009; 33:547-58; PMID:19285939; http://dx.doi.org/10. 1016/j.molcel.2009.01.024.
4. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003; 421:499-506; PMID:12556884; http://dx.doi.org/10.1038/nature01368.
5. Chapman JR, Taylor MR, Boulton SJ. Playing the end game: DNA double-strand break repair pathway choice. Mol Cell 2012; 47:497-510; PMID:22920291; http://dx.doi.org/10.1016/j.molcel.2012.07.029.
6. Kanu N, Behrens A. ATMIN defines an NBS1-independent pathway of ATM signalling. EMBO J 2007; 26:2933-41; PMID:17525732; http://dx.doi.org/10.1038/ sj.emboj.7601733.
7. Jazayeri A, Falck J, Lukas C, Bartek J, Smith GCM, Lukas J, et al. ATM-And cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol 2006; 8:37-45; PMID:16327781; http://dx.doi.org/10.1038/ ncb1337.
8. Houldsworth J, Lavin MF. Effect of ionizing radiation on synthesis of sub-replicon size DNA in ataxia telangiectasia cells. Biochem Int 1983; 6:349-56; PMID:6679327.
9. Kozlov SV, Graham ME, Jakob B, Tobias F, Kijas AW, Tanuji M, et al. Autophosphorylation and ATM activation: additional sites add to the complexity. J Biol Chem 2011; 286:9107-19; PMID:21149446; http://dx.doi.org/10.1074/jbc. M110.204065.
10. Guo Z, Kozlov S, Lavin MF, Person MD, Paull TT. ATM activation by oxidative stress. Science 2010; 330:517-21; PMID:20966255; http://dx.doi.org/10. 1126/science.1192912.
11. Nam EA, Cortez D. ATR signalling: more than meeting at the fork. Biochem J 2011; 436:527-36; PMID:21615334; http://dx.doi.org/10.1042/BJ20102162.
12. Ball HL, Cortez D. ATRIP oligomerization is required for ATR-dependent checkpoint signaling. J Biol Chem 2005; 280:31390-6; PMID:16027118; http://dx.doi.org/10.1074/jbc.M504961200.
13. Nam EA, Zhao R, Glick GG, Bansbach CE, Friedman DB, Cortez D. Thr-1989 phosphorylation is a marker of active ataxia telangiectasia-mutated and Rad3-related (ATR) kinase. J Biol Chem 2011; 286:28707-14; PMID:21705319; http://dx.doi.org/10.1074/jbc. M111.248914.
14. Pawelczak KS, Bennett SM, Turchi JJ. Coordination of DNA-PK activation and nuclease processing of DNA termini in NHEJ. Antioxid Redox Signal 2011; 14:2531-43; PMID:20698792; http://dx.doi.org/10.1089/ars.2010.3368.
15. Dobbs TA, Palmer P, Maniou Z, Lomax ME, O'Neill P. Interplay of two major repair pathways in the processing of complex double-strand DNA breaks. DNA Repair (Amst) 2008; 7:1372-83; PMID:18571480; http://dx.doi.org/10.1016/j. dnarep.2008.05.001.
16. Singleton BK, Torres-Arzayus MI, Rottinghaus ST, Taccioli GE, Jeggo PA. The C terminus of Ku80 activates the DNA-dependent protein kinase catalytic subunit. Mol Cell Biol 1999; 19:3267-77; PMID:10207052.
17. Gell D, Jackson SP. Mapping of protein-protein interactions within the DNA-dependent protein kinase complex. Nucleic Acids Res 1999; 27:3494-502; PMID:10446239; http://dx.doi.org/10.1093/nar/27.17.3494.
18. Weterings E, Verkaik NS, Keijzers G, Florea BI, Wang SY, Ortega LG, et al. The Ku80 carboxy terminus stimulates joining and artemis-mediated processing of DNA ends. Mol Cell Biol 2009; 29:1134-42; PMID:19103741; http://dx.doi.org/10.1128/MCB.00971-08.
19. Bennett SM, Woods DS, Pawelczak KS, Turchi JJ. Multiple protein-protein interactions within the DNA-PK complex are mediated by the C-terminus of Ku 80. Int J Biochem Mol Biol 2012; 3:36-45; PMID:22509479.
20. Hammel M, Yu Y, Mahaney BL, Cai B, Ye R, Phipps BM, et al. Ku and DNA-dependent protein kinase dynamic conformations and assembly regulate DNA binding and the initial non-homologous end joining complex. J Biol Chem 2010; 285:1414-23; PMID:19893054; http://dx.doi.org/10.1074/jbc. M109.065615.
21. Pawelczak KS, Turchi JJ. A mechanism for DNAPK activation requiring unique contributions from each strand of a DNA terminus and implications for microhomology-mediated nonhomologous DNA end joining. Nucleic Acids Res 2008; 36:4022-31; PMID:18515838; http://dx.doi.org/10.1093/nar/gkn344.
22. Meek K, Douglas P, Cui X, Ding Q, Lees-Miller SP. trans Autophosphorylation at DNA-dependent protein kinase's two major autophosphorylation site clusters facilitates end processing but not end joining. Mol Cell Biol 2007; 27:3881-90; PMID:17353268; http://dx.doi.org/10. 1128/MCB.02366-06.
23. Neal JA, Dang V, Douglas P, Wold MS, Lees-Miller SP, Meek K. Inhibition of homologous recombination by DNA-dependent protein kinase requires kinase activity, is titratable, and is modulated by autophosphorylation. Mol Cell Biol 2011; 31:1719-33; PMID:21300785; http://dx.doi.org/10.1128/MCB.01298-10.
24. Chen BP, Uematsu N, Kobayashi J, Lerenthal Y, Krempler A, Yajima H, et al. Ataxia telangiectasia mutated (ATM) is essential for DNA-PKcs phosphorylations at the Thr-2609 cluster upon DNA double strand break. J Biol Chem 2007; 282:6582-7; PMID:17189255; http://dx.doi.org/10.1074/jbc. M611605200.
25. Yajima H, Lee KJ, Chen BP. ATR-dependent phosphorylation of DNA-dependent protein kinase catalytic subunit in response to UV-induced replication stress. Mol Cell Biol 2006; 26:7520-8; PMID:16908529; http://dx.doi.org/10.1128/MCB. 00048-06.
26. Peng Y, Woods RG, Beamish H, Ye R, Lees-Miller SP, Lavin MF, et al. Deficiency in the catalytic subunit of DNA-dependent protein kinase causes down-regulation of ATM. Cancer Res 2005; 65:1670-7; PMID:15753361; http://dx.doi.org/10.1158/0008-5472.CAN-04-3451.
27. Quennet V, Beucher A, Barton O, Takeda S, Löbrich M. CtIP and MRN promote non-homologous endjoining of etoposide-induced DNA double-strand breaks in G1. Nucleic Acids Res 2011; 39:2144-52; PMID:21087997; http://dx.doi.org/10. 1093/nar/gkq1175.
28. Langerak P, Mejia-Ramirez E, Limbo O, Russell P. Release of Ku and MRN from DNA ends by Mre11 nuclease activity and Ctp1 is required for homologous recombination repair of double-strand breaks. PLoS Genet 2011; 7:e1002271; PMID:21931565; http://dx.doi.org/10.1371/journal.pgen.1002271.
29. Sertic S, Pizzi S, Lazzaro F, Plevani P, Muzi-Falconi M. NER and DDR: classical music with new instruments. Cell Cycle 2012; 11:668-74; PMID:22373527; http://dx.doi.org/10.4161/cc.11.4.19117.
30. Shuck SC, Short EA, Turchi JJ. Eukaryotic nucleotide excision repair: from understanding mechanisms to influencing biology. Cell Res 2008; 18:64-72; PMID:18166981; http://dx.doi.org/10.1038/cr.2008.2.
31. Sertic S, Pizzi S, Cloney R, Lehmann AR, Marini F, Plevani P, et al. Human exonuclease 1 connects nucleotide excision repair (NER) processing with checkpoint activation in response to UV irradiation. Proc Natl Acad Sci U S A 2011; 108:13647-52; PMID:21808022; http://dx.doi.org/10.1073/pnas.1108547108.
32. Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol 2012; 13:411-24; PMID:22713970; http://dx.doi.org/10.1038/nrm3376.
33. Jackson SP. The DNA-damage response: new molecular insights and new approaches to cancer therapy. Biochem Soc Trans 2009; 37:483-94; PMID:19442242; http://dx.doi.org/10.1042/BST0370483.
34. Lukas J, Lukas C, Bartek J. More than just a focus: The chromatin response to DNA damage and its role in genome integrity maintenance. Nat Cell Biol 2011; 13:1161-9; PMID:21968989; http://dx.doi.org/10.1038/ncb2344.
35. Cleaver JE. γH2Ax: biomarker of damage or functional participant in DNA repair "all that glitters is not gold!". Photochem Photobiol 2011; 87:1230-9; PMID:21883247; http://dx.doi.org/10.1111/j.1751-1097.2011. 00995.x.
36. Riballo E, Kühne M, Rief N, Doherty A, Smith GCM, Recio MJ, et al. A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-H2AX foci. Mol Cell 2004; 16:715-24; PMID:15574327; http://dx.doi.org/10.1016/j.molcel.2004.10.029.
37. Cook PJ, Ju BG, Telese F, Wang X, Glass CK, Rosenfeld MG. Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions. Nature 2009; 458:591-6; PMID:19234442; http://dx.doi.org/10.1038/nature07849.
38. Jungmichel S, Stucki M. MDC1: The art of keeping things in focus. Chromosoma 2010; 119:337-49; PMID:20224865; http://dx.doi.org/10.1007/s00412- 010-0266-9.
39. Lowndes NF, Toh GW. DNA repair: the importance of phosphorylating histone H2AX. Curr Biol 2005; 15:R99-102; PMID:15694301; http://dx.doi.org/10.1016/j. cub.2005.01.029.
40. Yoo HY, Kumagai A, Shevchenko A, Shevchenko A, Dunphy WG. Ataxia-telangiectasia mutated (ATM)-dependent activation of ATR occurs through phosphorylation of TopBP1 by ATM. J Biol Chem 2007; 282:17501-6; PMID:17446169; http://dx.doi.org/10.1074/jbc.M701770200.
41. Shuck SC, Turchi JJ. Targeted inhibition of Replication Protein A reveals cytotoxic activity, synergy with chemotherapeutic DNA-damaging agents, and insight into cellular function. Cancer Res 2010; 70:3189-98; PMID:20395205; http://dx.doi.org/10.1158/0008-5472.CAN-09-3422.
42. Liu S, Opiyo SO, Manthey K, Glanzer JG, Ashley AK, Amerin C, et al. Distinct roles for DNA-PK, ATM and ATR in RPA phosphorylation and checkpoint activation in response to replication stress. Nucleic Acids Res 2012; 40:10780-94; PMID:22977173; http://dx.doi.org/10.1093/nar/gks849.
43. Serrano MA, Li Z, Dangeti M, Musich PR, Patrick S, Roginskaya M, et al. DNA-PK, ATM and ATR collaboratively regulate p53-RPA interaction to facilitate homologous recombination DNA repair. Oncogene 2012; PMID:22797063; http://dx.doi.org/10.1038/onc.2012.257.
44. Liaw H, Lee D, Myung K. DNA-PK-dependent RPA2 hyperphosphorylation facilitates DNA repair and suppresses sister chromatid exchange. PLoS One 2011; 6:e21424; PMID:21731742; http://dx.doi.org/10.1371/journal.pone.0021424.
45. Feng J, Wakeman T, Yong S, Wu X, Kornbluth S, Wang XF. Protein phosphatase 2A-dependent dephosphorylation of replication protein A is required for the repair of DNA breaks induced by replication stress. Mol Cell Biol 2009; 29:5696-709; PMID:19704001; http://dx.doi.org/10.1128/MCB.00191-09.
46. Flynn RL, Zou L. ATR: a master conductor of cellular responses to DNA replication stress. Trends Biochem Sci 2011; 36:133-40; PMID:20947357; http://dx.doi.org/10.1016/j.tibs.2010.09.005.
47. Wang X, Zou L, Lu T, Bao S, Hurov KE, Hittelman WN, et al. Rad17 phosphorylation is required for claspin recruitment and Chk1 activation in response to replication stress. Mol Cell 2006; 23:331-41; PMID:16885023; http://dx.doi.org/10.1016/j.molcel. 2006.06.022.
48. Reinhardt HC, Yaffe MB. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol 2009; 21:245-55; PMID:19230643; http://dx.doi.org/10.1016/j.ceb.2009.01.018.
49. Ahn JY, Schwarz JK, Piwnica-Worms H, Canman CE. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res 2000; 60:5934-6; PMID:11085506.
50. Ahn J, Urist M, Prives C. The Chk2 protein kinase. DNA Repair (Amst) 2004; 3:1039-47; PMID:15279791; http://dx.doi.org/10.1016/j.dnarep.2004.03.033.
51. Jin J, Ang XL, Ye X, Livingstone M, Harper JW. Differential roles for checkpoint kinases in DNA damage-dependent degradation of the Cdc25A protein phosphatase. J Biol Chem 2008; 283:19322-8; PMID:18480045; http://dx.doi.org/10. 1074/jbc. M802474200.
52. Jin J, Shirogane T, Xu L, Nalepa G, Qin J, Elledge SJ, et al. SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. Genes Dev 2003; 17:3062-74; PMID:14681206; http://dx.doi.org/10. 1101/gad.1157503.
53. Ferguson AM, White LS, Donovan PJ, Piwnica-Worms H. Normal cell cycle and checkpoint responses in mice and cells lacking Cdc25B and Cdc25C protein phosphatases. Mol Cell Biol 2005; 25:2853-60; PMID:15767688; http://dx.doi.org/10.1128/MCB.25.7.2853-2860.2005.
54. Lopergolo A, Tavecchio M, Lisanti S, Ghosh JC, Dohi T, Faversani A, et al. Chk2 phosphorylation of survivin-DeltaEx3 contributes to a DNA damage-sensing checkpoint in cancer. Cancer Res 2012; 72:3251-9; PMID:22586065; http://dx.doi.org/10.1158/0008-5472.CAN-11-4035.
55. Ilves I, Tamberg N, Botchan MR. Checkpoint kinase 2 (Chk2) inhibits the activity of the Cdc45/MCM2-7/GINS (CMG) replicative helicase complex. Proc Natl Acad Sci U S A 2012; 109:13163-70; PMID:22853956; http://dx.doi.org/10.1073/ pnas.1211525109.
56. Hu J, Sun L, Shen F, Chen Y, Hua Y, Liu Y, et al. The intra-S phase checkpoint targets Dna2 to prevent stalled replication forks from reversing. Cell 2012; 149:1221-32; PMID:22682245; http://dx.doi.org/10.1016/j.cell.2012.04. 030.
57. Keating MJ, Bach C, Yasothan U, Kirkpatrick P. Bendamustine. Nat Rev Drug Discov 2008; 7:473-4; PMID:18511926; http://dx.doi.org/10.1038/nrd2596.
58. Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008; 14:309-17; PMID:18172283; http://dx.doi.org/10.1158/1078-0432.CCR-07-1061.
59. Hartmann M, Zimmer C. Investigation of crosslink formation in DNA by the alkylating cytostatic IMET 3106, 3393 and 3943. Biochim Biophys Acta 1972; 287:386-9; PMID:4629776; http://dx.doi.org/10.1016/0005-2787(72)90282-1.
60. Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 1996; 7:415-21; PMID:8826610; http://dx.doi.org/10. 1097/00001813-199606000-00007.
61. Episkopou H, Kyrtopoulos SA, Sfikakis PP, Fousteri M, Dimopoulos MA, Mullenders LH, et al. Association between transcriptional activity, local chromatin structure, and the efficiencies of both subpathways of nucleotide excision repair of melphalan adducts. Cancer Res 2009; 69:4424-33; PMID:19417135; http://dx.doi.org/10.1158/0008-5472.CAN-08-3489.
62. Gaul L, Mandl-Weber S, Baumann P, Emmerich B, Schmidmaier R. Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATMChk2-Cdc25A and ATM-p53-p21-pathways. J Cancer Res Clin Oncol 2008; 134:245-53; PMID:17653574; http://dx.doi.org/10.1007/s00432-007-0278-x.
63. Landau HJ, McNeely SC, Nair JS, Comenzo RL, Asai T, Friedman H, et al. The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells. Mol Cancer Ther 2012; 11:1781-8; PMID:22653969; http://dx.doi.org/10.1158/1535-7163.MCT-11-0949.
64. Beeharry N, Rattner JB, Bellacosa A, Smith MR, Yen TJ. Dose dependent effects on cell cycle checkpoints and DNA repair by bendamustine. PLoS One 2012; 7:e40342; PMID:22768280; http://dx.doi.org/10.1371/journal.pone.0040342.
65. Jalal S, Earley JN, Turchi JJ. DNA repair: from genome maintenance to biomarker and therapeutic target. Clin Cancer Res 2011; 17:6973-84; PMID:21908578; http://dx.doi.org/10.1158/1078-0432.CCR-11-0761.
66. Cruet-Hennequart S, Glynn MT, Murillo LS, Coyne S, Carty MP. Enhanced DNA-PK-mediated RPA2 hyperphosphorylation in DNA polymerase eta-deficient human cells treated with cisplatin and oxaliplatin. DNA Repair (Amst) 2008; 7:582-96; PMID:18289945; http://dx.doi.org/10.1016/j.dnarep.2007.12.012.
67. Pabla N, Huang S, Mi QS, Daniel R, Dong Z. ATRChk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J Biol Chem 2008; 283:6572-83; PMID:18162465; http://dx.doi.org/10.1074/jbc.M707568200.
68. Colton SL, Xu XS, Wang YA, Wang G. The involvement of ataxia-telangiectasia mutated protein activation in nucleotide excision repair-facilitated cell survival with cisplatin treatment. J Biol Chem 2006; 281:27117-25; PMID:16849332; http://dx.doi.org/10.1074/jbc.M602826200.
69. Sangster-Guity N, Conrad BH, Papadopoulos N, Bunz F. ATR mediates cisplatin resistance in a p53 genotype-specific manner. Oncogene 2011; 30:2526-33; PMID:21258400; http://dx.doi.org/10.1038/onc.2010.624.
70. Lewis KA, Lilly KK, Reynolds EA, Sullivan WP, Kaufmann SH, Cliby WA. Ataxia telangiectasia and rad3-related kinase contributes to cell cycle arrest and survival after cisplatin but not oxaliplatin. Mol Cancer Ther 2009; 8:855-63; PMID:19372558; http://dx.doi.org/10.1158/1535-7163.MCT-08-1135.
71. Prevo R, Fokas E, Reaper PM, Charlton PA, Pollard JR, McKenna WG, et al. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biol Ther 2012; 13:1072-81; PMID:22825331; http://dx.doi.org/10.4161/cbt.21093.
72. Peasland A, Wang LZ, Rowling E, Kyle S, Chen T, Hopkins A, et al. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br J Cancer 2011; 105:372-81; PMID:21730979; http://dx.doi.org/10.1038/bjc.2011.243.
73. Zhao H, Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol 2001; 21:4129-39; PMID:11390642; http://dx.doi.org/10.1128/MCB.21.13.4129-4139.2001.
74. Fuse E, Kuwabara T, Sparreboom A, Sausville EA, Figg WD. Review of UCN-01 development: a lesson in the importance of clinical pharmacology. J Clin Pharmacol 2005; 45:394-403; PMID:15778420; http://dx.doi.org/10.1177/ 0091270005274549.
75. Wagner JM, Karnitz LM. Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival. Mol Pharmacol 2009; 76:208-14; PMID:19403702; http://dx.doi.org/10.1124/mol. 109.055178.
76. Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 2000; 87:227-53; PMID:11008002; http://dx.doi.org/10.1016/S0163- 7258(00)00086-3.
77. Karnitz LM, Flatten KS, Wagner JM, Loegering D, Hackbarth JS, Arlander SJ, et al. Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol Pharmacol 2005; 68:1636-44; PMID:16126823.
78. Huelsenbeck SC, Schorr A, Roos WP, Huelsenbeck J, Henninger C, Kaina B, et al. Rac1 protein signaling is required for DNA damage response stimulated by topoisomerase II poisons. J Biol Chem 2012; 287:38590-9; PMID:23012366; http://dx.doi.org/10.1074/jbc.M112.377903.
79. Flatten K, Dai NT, Vroman BT, Loegering D, Erlichman C, Karnitz LM, et al. The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons. J Biol Chem 2005; 280:14349-55; PMID:15699047; http://dx.doi.org/10.1074/jbc. M411890200.
80. Kennedy DR, Beerman TA. The radiomimetic enediyne C-1027 induces unusual DNA damage responses to double-strand breaks. Biochemistry 2006; 45:3747-54; PMID:16533058; http://dx.doi.org/10.1021/bi052334c.
81. Kennedy DR, Ju J, Shen B, Beerman TA. Designer enediynes generate DNA breaks, interstrand crosslinks, or both, with concomitant changes in the regulation of DNA damage responses. Proc Natl Acad Sci U S A 2007; 104:17632-7; PMID:17978180; http://dx.doi.org/10.1073/pnas.0708274104.